Respiratory Disorders Therapeutics Market to 2017 by GBIResearch

VIEWS: 44 PAGES: 171

More Info
									    Respiratory Disorders Therapeutics Market to 2017 - Novel
     Pipeline Molecules such as VX-770 and pirfenidone May
             Offset Negative Effect of Patent Expiries
 Reference Code: GBIHC132MR                                                                                             Publication Date: September 2011


     The global respiratory           Patent Expiries and Generic Competition Are Negatively Impacting upon the Market,
     therapeutics market was          Reducing its CAGR from 7.7% in 2002-2010 to 3.1% in 2010-2017
     valued at $30.1 billion in
     2010 and is expected to           Respiratory Disorders Therapeutics Market, Global, Revenue Forecasts ($bn), 2002-2017
     grow to $37.4 billion by
     2017 at a Compound                                   40
     Annual Growth Rate
     (CAGR) of 3.1%.                                           CAGR (2002-2010) - 7.7%
                                                          35
                                                               CAGR (2010-2017) - 3.1%


                                                          30



                                                          25
                                          Revenue ($bn)




                                                          20



                                                          15



                                                          10



                                                           5



                                                           0
                                                                       2002                               2010                               2017


                                       Source: GBI Research, Centre for Disease Prevention and Control (CDC),Food and Drug Administration (FDA), National
                                       Heart Lung and Blood Institute, American journal of Respiratory and Critical Medicine, Journal of Investigational Allergology
                                       and Clinical Immunology, Primary Care Respiratory Journal, Americanheart, AHA Journal, PH Association



                                      The global respiratory therapeutics market was valued at $30.1 billion in 2010 and is expected to
                                      grow to $37.4 billion by 2017 at a Compound Annual Growth Rate (CAGR) of 3.1%. In 2010,
                                      approximately 49 million patients received pharmacological treatment for respiratory disorders with
                                      the annual cost of therapy being $611 per year. In addition, the annual cost of therapy for the
                                      respiratory disorders therapeutic area is expected to increase at a gradual rate over the following
                                      year. The respiratory disorders market growth rate will witness a decline during 2010-2017. This
                                      decline can be attributed to the patent expiries of certain branded products such as Tracleer
                                      (bosentan), Singulair (montelukast), Symbicort (budesonide and formoterol inhalation), Nasonex
                                      (mometasone furoate monohydrate), Rhinocort (budesonide) and Advair (fluticasone and
                                      salmeterol).
                                      The market is projected to face increased competition from generic drugs. Patent expiries coupled
                                      with generic competition will reduce the annual cost of therapy in the forecast period. However, the
                                      annual cost of therapy will witness a moderate increase at a CAGR of 0.1% in the forecast period.
                                      This can be attributed to the launch of new pipeline molecules such as VX-770 and Riociguat (BAY
                                      63-2521).




Respiratory Disorders Therapeutics Market to 2017 - Novel                                                                   GBIHC132MR /Published SEP 2011
Pipeline Molecules such as VX-770 and pirfenidone May
Offset Negative Effect of Patent Expiries                                                                                                                     Page 1
                                                                                         © GBI Research. This is a licensed product and is not to be photocopied
                                      Global Generic Share in Respiratory Disorders will Increase by 4% in the Forecast Period

                                      Generic drugs are projected to contribute 49% to the respiratory disorders therapeutics market in
                                      2017. This can be attributed to the patent expiry of branded products such as Tracleer, Symbicort,
                                      Singulair, Nasonex, Advair, Rhinocort, Pulmozyme (dornase alfa), TOBI (tobramycin) and Clarinex
                                      (desloratadine). The drugs are used in the treatment of various respiratory disorders such as
                                      asthma, chronic obstructive pulmonary disease (COPD), allergic rhinitis and idiopathic pulmonary
                                      fibrosis. These patent expirations will negatively impact upon the respiratory disorders therapeutics
                                      market. However, the moderate rate of growth in the forecast period can be attributed to the launch
                                      of new pipeline molecules which such as VX-770 and Indacaterol in the forecast period. In 2017 the
                                      branded drugs are projected to contribute 51% to the respiratory disorders therapeutics market.

                                       Respiratory Disorders Therapeutics Market, Global, Branded and Generic Share (%), 2010




                                                                           2010,
                                                                   2017,   45%
                                                                   49%                                                       2017,
                                                                                                                     2010,   51%
                                                                                                                     55%




                                                                                         Branded      Generic

                                       Source: GBI Research, CDC, FDA, National Heart Lung and Blood Institute, American journal of Respiratory and Critical
                                       Medicine, Journal of Investigational Allergology and Clinical Immunology, Primary Care Respiratory Journal, Americanheart,
                                       AHA Journal, PH Association



                                      Deals Worth Less than $200m Accounted for 62% of Strategic Consolidations

                                      Strategic consolidations help a company to enter a new market or consolidate its position in the
                                      market. The majority (62%) of the merger and acquisition (M&A) deals in the respiratory
                                      therapeutics market were worth less than $200m. SciClone Pharmaceuticals, Inc acquired
                                      Novamed Pharmaceuticals Inc, enabling SciClone to increase its sales and enter the Chinese
                                      market. The market has witnessed numerous strategic consolidations. The US market witnessed
                                      the highest number of M&A deals at various levels. North America witnessed 45% of the strategic
                                      consolidation in the period 2004-2011. The highest value deal in the year 2011 was Forest
                                      Laboratories completes acquisition of Clinical Data for $1,200m.




Respiratory Disorders Therapeutics Market to 2017 - Novel                                                                GBIHC132MR /Published SEP 2011
Pipeline Molecules such as VX-770 and pirfenidone May
Offset Negative Effect of Patent Expiries                                                                                                                 Page 2
                                                                                 © GBI Research. This is a licensed product and is not to be photocopied
                                      1      Table of Contents
                                      1   Table of Contents ........................................................................................................................ 3
                                          1.1    List of Tables..................................................................................................................... 6
                                          1.2    List of Figures ................................................................................................................. 10
                                      2   Respiratory Disorders Therapeutics Market to 2017 - Introduction............................................ 13
                                          2.1    GBI Research Report Guidance ..................................................................................... 14
                                      3   Respiratory Disorders Therapeutics Market to 2017 - Market Overview ................................... 15
                                          3.1    Introduction ..................................................................................................................... 15
                                          3.2    Revenue Forecasts for Respiratory Disorders Therapeutics Market............................... 15
                                             3.2.1    Revenues ................................................................................................................ 15
                                             3.2.2    Annual Cost of Therapy ........................................................................................... 20
                                          3.3    Treatment Usage Patterns .............................................................................................. 21
                                          3.4    Drivers and Barriers for Respiratory Disorders Therapeutics Market .............................. 23
                                             3.4.1    Drivers for Respiratory Disorders ............................................................................ 23
                                             3.4.2    Barriers for Respiratory Disorders ........................................................................... 24
                                      4   Respiratory Disorders Therapeutics Market to 2017 - Geographical Landscape ...................... 25
                                          4.1    The US ............................................................................................................................ 25
                                             4.1.1    Revenue .................................................................................................................. 25
                                             4.1.2    Annual Cost of Therapy ........................................................................................... 26
                                             4.1.3    Treatment Usage Pattern ........................................................................................ 27
                                          4.2    Top Five Countries of Europe ......................................................................................... 29
                                             4.2.1    Revenue .................................................................................................................. 29
                                             4.2.2    Annual Cost of Therapy ........................................................................................... 32
                                             4.2.3    Treatment Usage Pattern ........................................................................................ 33
                                          4.3    Japan .............................................................................................................................. 35
                                             4.3.1    Revenue .................................................................................................................. 35
                                             4.3.2    Annual Cost of Therapy ........................................................................................... 36
                                             4.3.3    Treatment Usage Pattern ........................................................................................ 37
                                      5   Respiratory Disorders Therapeutics Market to 2017 - Therapeutic Landscape ......................... 39
                                          5.1    Asthma ............................................................................................................................ 39
                                             5.1.1    Introduction .............................................................................................................. 39
                                             5.1.2    Revenue .................................................................................................................. 39
                                             5.1.3    Annual Cost of Therapy ........................................................................................... 44
                                             5.1.4    Treatment Usage Patterns ...................................................................................... 45
                                             5.1.5    Treatment Flow Algorithm ....................................................................................... 47
                                             5.1.6    Drivers and Barriers for Asthma .............................................................................. 48
                                          5.2    COPD ............................................................................................................................. 50
                                             5.2.1    Introduction .............................................................................................................. 50
                                             5.2.2    Revenue .................................................................................................................. 50
                                             5.2.3    Annual Cost of Therapy ........................................................................................... 55
                                             5.2.4    Treatment Usage Patterns ...................................................................................... 56
                                             5.2.5    Treatment Flow Algorithm ....................................................................................... 58
                                             5.2.6    Drivers and Barriers for COPD ................................................................................ 59
                                          5.3    Pulmonary Arterial Hypertension .................................................................................... 60
                                             5.3.1    Introduction .............................................................................................................. 60
                                             5.3.2    Revenue .................................................................................................................. 62
                                             5.3.3    Annual Cost of Therapy ........................................................................................... 66
                                             5.3.4    Treatment Usage Patterns ...................................................................................... 67
                                             5.3.5    Treatment Flow Algorithm ....................................................................................... 69
                                             5.3.6    Drivers and Barriers for Pulmonary Arterial Hypertension ....................................... 70
                                          5.4    Cystic Fibrosis................................................................................................................. 71
                                             5.4.1    Introduction .............................................................................................................. 71
                                             5.4.2    Revenue .................................................................................................................. 71
                                             5.4.3    Annual Cost of Therapy ........................................................................................... 76


Respiratory Disorders Therapeutics Market to 2017 - Novel                                                                              GBIHC132MR /Published SEP 2011
Pipeline Molecules such as VX-770 and pirfenidone May
Offset Negative Effect of Patent Expiries                                                                                                                                     Page 3
                                                                                        © GBI Research. This is a licensed product and is not to be photocopied
                                           5.4.4    Treatment Usage Patterns ...................................................................................... 77
                                           5.4.5    Treatment Flow Algorithm ....................................................................................... 79
                                           5.4.6    Drivers and Barriers for Cystic Fibrosis ................................................................... 80
                                        5.5    Allergic Rhinitis ............................................................................................................... 81
                                           5.5.1    Introduction .............................................................................................................. 81
                                           5.5.2    Revenue .................................................................................................................. 81
                                           5.5.3    Annual Cost of Therapy ........................................................................................... 86
                                           5.5.4    Treatment Usage Patterns ...................................................................................... 87
                                           5.5.5    Treatment Flow Algorithm ....................................................................................... 88
                                           5.5.6    Drivers and Barriers for Allergic Rhinitis .................................................................. 89
                                        5.6    Idiopathic Pulmonary Fibrosis ......................................................................................... 90
                                           5.6.1    Introduction .............................................................................................................. 90
                                           5.6.2    Revenue .................................................................................................................. 90
                                           5.6.3    Annual Cost of Therapy ........................................................................................... 94
                                           5.6.4    Treatment Usage Patterns ...................................................................................... 95
                                           5.6.5    Treatment Flow Algorithm ....................................................................................... 97
                                           5.6.6    Drivers and Barriers for Idiopathic Pulmonary Fibrosis............................................ 98
                                        5.7    Bronchitis ........................................................................................................................ 99
                                           5.7.1    Introduction .............................................................................................................. 99
                                           5.7.2    Revenue .................................................................................................................. 99
                                           5.7.3    Annual Cost of Therapy ......................................................................................... 104
                                           5.7.4    Treatment Usage Patterns .................................................................................... 105
                                           5.7.5    Treatment Flow Algorithm ..................................................................................... 107
                                           5.7.6    Drivers and Barriers for Bronchitis ......................................................................... 108
                                      6 Respiratory Disorders Therapeutics Market to 2017 - Product Pipeline Analysis .................... 109
                                        6.1    Introduction ................................................................................................................... 109
                                           6.1.1    Research and Development Pipeline - Asthma ..................................................... 111
                                           6.1.2    Research and Development Pipeline - COPD ....................................................... 117
                                           6.1.3    Research and Development Pipeline - Pulmonary Arterial Hypertension .............. 121
                                           6.1.4    Research and Development Pipeline - Cystic Fibrosis .......................................... 123
                                           6.1.5    Research and Development Pipeline - Allergic Rhinitis ......................................... 125
                                           6.1.6    Research and Development Pipeline - Idiopathic Pulmonary Fibrosis .................. 128
                                           6.1.7    Research and Development Pipeline - Bronchitis.................................................. 130
                                        6.2    Profiles of Promising Drugs in the Respiratory Disorders Therapeutics Market ............ 131
                                           6.2.1    Bilastine ................................................................................................................. 131
                                           6.2.2    Sublivac (Extracts of Allergens) ............................................................................. 131
                                           6.2.3    Duonase (Azelastine + Fluticasone) ...................................................................... 132
                                           6.2.4    Riociguat ............................................................................................................... 133
                                           6.2.5    VX-770 .................................................................................................................. 133
                                           6.2.6    Indacaterol ............................................................................................................. 134
                                           6.2.7    NVA237 (Glycopyrronium Bromide) ...................................................................... 135
                                           6.2.8    Aclidinium Bromide ................................................................................................ 136
                                      7 Respiratory Disorders Therapeutics Market to 2017 - Competitive Landscape ....................... 137
                                        7.1    Market Share Analysis: Respiratory Disorders Market.................................................. 137
                                        7.2    Drug Profile of Major Marketed Products ...................................................................... 138
                                           7.2.1    Advair Diskus (fluticasone propionate and salmeterol inhalation powder) ............. 138
                                           7.2.2    Symbicort (budesonide/formoterol fumarate dihydrate inhalation aerosol) ............ 140
                                           7.2.3    Singulair (montekeulast sodium) ........................................................................... 141
                                           7.2.4    Tracleer ................................................................................................................. 142
                                           7.2.5    Nasonex (mometasone furoate monohydrate) ...................................................... 143
                                        7.3    Competitive Profiling ..................................................................................................... 145
                                           7.3.1    AstraZeneca .......................................................................................................... 145
                                           7.3.2    GlaxoSmithKline .................................................................................................... 147
                                           7.3.3    Merck & Co., Inc. ................................................................................................... 149
                                           7.3.4    Actelion .................................................................................................................. 151

Respiratory Disorders Therapeutics Market to 2017 - Novel                                                                             GBIHC132MR /Published SEP 2011
Pipeline Molecules such as VX-770 and pirfenidone May
Offset Negative Effect of Patent Expiries                                                                                                                                  Page 4
                                                                                        © GBI Research. This is a licensed product and is not to be photocopied
                                           7.3.5    Novartis ................................................................................................................. 153
                                      8 Respiratory Disorders Therapeutics Market to 2017 - M&A Landscape .................................. 155
                                        8.1    M&A Landscape............................................................................................................ 155
                                           8.1.1    M&A Deals by Year ............................................................................................... 155
                                           8.1.2    M&A Deals by Value.............................................................................................. 156
                                           8.1.3    M&A Deals by Value ($) ........................................................................................ 156
                                           8.1.4    M&A Deals by Geography ..................................................................................... 157
                                           8.1.5    M&A Deals by Deal Type ...................................................................................... 158
                                           8.1.6    M&A Deals by Deal Sub-Type ............................................................................... 159
                                        8.2    R&D Licensing Agreements .......................................................................................... 160
                                           8.2.1    Deals by Year ........................................................................................................ 160
                                           8.2.2    Deals by Geography .............................................................................................. 161
                                           8.2.3    Deals by Value ($) ................................................................................................. 162
                                           8.2.4    Licensing Agreements by Value ($) ....................................................................... 162
                                        8.3    Co-Development Agreements ....................................................................................... 163
                                           8.3.1    Deals by Year ........................................................................................................ 163
                                           8.3.2    Deals by Geography .............................................................................................. 164
                                      9 Respiratory Disorders Therapeutics Market to 2017 - Appendix ............................................. 165
                                        9.1    Market Definitions ......................................................................................................... 165
                                        9.2    Abbreviations ................................................................................................................ 165
                                        9.3    Research Methodology ................................................................................................. 166
                                           9.3.1    Coverage ............................................................................................................... 166
                                           9.3.2    Secondary Research ............................................................................................. 166
                                           9.3.3    Primary Research .................................................................................................. 167
                                           9.3.4    Section Wise Methodology .................................................................................... 167
                                           9.3.5    Expert Panel Validation ......................................................................................... 170
                                        9.4    Contact Us .................................................................................................................... 170
                                        9.5    Disclaimer ..................................................................................................................... 171
                                        9.6    Sources ......................................................................................................................... 171




Respiratory Disorders Therapeutics Market to 2017 - Novel                                                                            GBIHC132MR /Published SEP 2011
Pipeline Molecules such as VX-770 and pirfenidone May
Offset Negative Effect of Patent Expiries                                                                                                                                 Page 5
                                                                                       © GBI Research. This is a licensed product and is not to be photocopied
                                      1.1    List of Tables
                                      Table 1:    Respiratory Disorders Therapeutics Market, Global, Revenue ($bn), 2002-2010 .......... 15
                                      Table 2:    Respiratory Disorders Therapeutics Market, Global, Revenue Forecasts ($bn), 2010-
                                                  2017 ............................................................................................................................... 16
                                      Table 3:    Respiratory Disorders Therapeutics Market, Global, Geographical Segmentation ($bn),
                                                  2002-2010 ...................................................................................................................... 17
                                      Table 4:    Respiratory Disorders Therapeutics Market, Global, Geographical Segmentation ($bn),
                                                  2010-2017 ...................................................................................................................... 18
                                      Table 5:    Respiratory Disorders Therapeutics Market, Global, Annual Cost of Therapy ($), 2002-
                                                  2010 ............................................................................................................................... 20
                                      Table 6:    Respiratory Disorders Therapeutics Market, Global, Annual Cost of Therapy ($), 2010-
                                                  2017 ............................................................................................................................... 20
                                      Table 7:    Respiratory Disorders Therapeutics Market, Global, Treatment Usage Patterns (million),
                                                  2002-2010 ...................................................................................................................... 21
                                      Table 8:    Respiratory Disorders Therapeutics Market, Global, Treatment Usage Patterns (million),
                                                  2010-2017 ...................................................................................................................... 22
                                      Table 9:    Respiratory Disorders Therapeutics Market, The US, Revenue, ($bn), 2002-2010 ....... 25
                                      Table 10:   Respiratory Disorders Therapeutics Market, The US, Revenue Forecasts, ($bn), 2010-
                                                  2017 ............................................................................................................................... 25
                                      Table 11:   Respiratory Disorders Therapeutics Market, The US, Annual Cost of Therapy, ($), 2002-
                                                  2010 ............................................................................................................................... 26
                                      Table 12:   Respiratory Disorders Therapeutics Market, The US, Annual Cost of Therapy, ($), 2010-
                                                  2017 ............................................................................................................................... 26
                                      Table 13:   Respiratory Disorders Therapeutics Market, The US, Treatment Usage Patterns,
                                                  (million), 2002-2010 ....................................................................................................... 27
                                      Table 14:   Respiratory Disorders Therapeutics Market, The US, Treatment Usage Patterns,
                                                  (million), 2010-2017 ....................................................................................................... 28
                                      Table 15:   Respiratory Disorders Therapeutics Market, Top Five Countries, Revenue, ($bn), 2002-
                                                  2010 ............................................................................................................................... 29
                                      Table 16:   Respiratory Disorders Therapeutics Market, Top Five Countries, Revenue, ($bn), 2010-
                                                  2017 ............................................................................................................................... 29
                                      Table 17:   Respiratory Disorders Therapeutics Market, Top Five Countries of Europe, Revenue
                                                  Share by Country, ($bn), 2002-2010 .............................................................................. 30
                                      Table 18:   Respiratory Disorders Therapeutics Market, Top Five Countries of Europe, Revenue
                                                  Forecasts, ($bn), 2010-2017 .......................................................................................... 31
                                      Table 19:   Respiratory Disorders Therapeutics Market, Top Five Countries of Europe, Annual Cost
                                                  of Therapy, ($), 2002-2010 ............................................................................................ 32
                                      Table 20:   Respiratory Disorders Therapeutics Market, Top Five Countries of Europe, Annual Cost
                                                  of Therapy, ($), 2010-2017 ............................................................................................ 32
                                      Table 21:   Respiratory Disorders Therapeutics Market, Top Five Countries of Europe, Treatment
                                                  Usage Patterns, (million), 2002-2010 ............................................................................. 33
                                      Table 22:   Respiratory Disorders Therapeutics Market, Top Five Countries of Europe, Treatment
                                                  Usage Patterns, (million), 2010-2017 ............................................................................. 34
                                      Table 23:   Respiratory Disorders Therapeutics Market, Japan, Revenue, ($bn), 2002-2010 ......... 35
                                      Table 24:   Respiratory Disorders Therapeutics Market, Japan, Revenue Forecasts, ($bn), 2010-
                                                  2017 ............................................................................................................................... 35
                                      Table 25:   Respiratory Disorders Therapeutics Market, Japan, Annual Cost of Therapy, ($), 2002-
                                                  2010 ............................................................................................................................... 36
                                      Table 26:   Respiratory Disorders Therapeutics Market, Japan, Annual Cost of Therapy, ($), 2010-
                                                  2017 ............................................................................................................................... 36
                                      Table 27:   Respiratory Disorders Therapeutics Market, Japan, Treatment Usage Patterns, (million),
                                                  2002-2010 ...................................................................................................................... 37
                                      Table 28:   Respiratory Disorders Therapeutics Market, Japan, Treatment Usage Patterns, (million),
                                                  2010-2017 ...................................................................................................................... 38
                                      Table 29:   Asthma Therapeutics Market, Global, Revenue, ($bn), 2002-2010 ............................... 40
                                      Table 30:   Asthma Therapeutics Market, Global, Revenue Forecasts, ($bn), 2010-2017............... 40
                                      Table 31:   Asthma Therapeutics Market, Global, Geographical Segmentation, ($bn), 2002-2010 41
                                      Table 32:   Asthma Therapeutics Market, Global, Geographical Segmentation, ($bn), 2010-2017 42
                                      Table 33:   Asthma Therapeutics Market, Global, Annual Cost of Therapy, ($), 2002-2010 ............ 44
                                      Table 34:   Asthma Therapeutics Market, Global, Annual Cost of Therapy, ($), 2010-2017 ............ 44
                                      Table 35:   Asthma Therapeutics Market, Global, Treatment Usage Patterns, (million), 2002-2010
                                                  ....................................................................................................................................... 45

Respiratory Disorders Therapeutics Market to 2017 - Novel                                                                                GBIHC132MR /Published SEP 2011
Pipeline Molecules such as VX-770 and pirfenidone May
Offset Negative Effect of Patent Expiries                                                                                                                                        Page 6
                                                                                       © GBI Research. This is a licensed product and is not to be photocopied
                                      Table 36:   Asthma Therapeutics Market, Global, Treatment Usage Patterns, (million), 2010-2017 46
                                      Table 37:   COPD Therapeutics Market, Global, Revenue, ($m), 2002-2010 .................................. 51
                                      Table 38:   COPD Therapeutics Market, Global, Revenue Forecasts, ($m), 2010-2017 ................. 51
                                      Table 39:   COPD Therapeutics Market, Global, Geographical Segmentation, ($m), 2002-2010 ... 52
                                      Table 40:   COPD Therapeutics Market, Global, Geographical Segmentation, ($m), 2010-2017 ... 53
                                      Table 41:   COPD Therapeutics Market, Global, Annual Cost of Therapy, ($), 2002-2010 .............. 55
                                      Table 42:   COPD Therapeutics Market, Global, Annual Cost of Therapy, ($), 2010-2017 .............. 55
                                      Table 43:   COPD Therapeutics Market, Global, Treatment Usage Patterns, (million), 2002-2010 56
                                      Table 44:   COPD Therapeutics Market, Global, Treatment Usage Patterns, (million), 2010-2017 57
                                      Table 45:   Pulmonary Arterial Hypertension Therapeutics Market, Global, Revenue, ($m), 2002-
                                                  2010 ............................................................................................................................... 62
                                      Table 46:   Pulmonary Arterial Hypertension Therapeutics Market, Global, Revenue Forecasts,
                                                  ($m), 2010-2017............................................................................................................. 62
                                      Table 47:   Pulmonary Arterial Hypertension Therapeutics Market, Global, Geographical
                                                  Segmentation, ($m), 2002-2010..................................................................................... 63
                                      Table 48:   Pulmonary Arterial Hypertension Therapeutics Market, Global, Geographical
                                                  Segmentation, ($m), 2010-2017..................................................................................... 64
                                      Table 49:   Pulmonary Arterial Hypertension Therapeutics Market, Global, Annual Cost of Therapy,
                                                  ($), 2002-2010................................................................................................................ 66
                                      Table 50:   Pulmonary Arterial Hypertension Therapeutics Market, Global, Annual Cost of Therapy,
                                                  ($), 2010-2017................................................................................................................ 66
                                      Table 51:   Pulmonary Arterial Hypertension Therapeutics Market, Global, Treatment Usage
                                                  Patterns, (‘000), 2002-2010 ........................................................................................... 67
                                      Table 52:   Pulmonary Arterial Hypertension Therapeutics Market, Global, Treatment Usage
                                                  Patterns, (‘000), 2010-2017 ........................................................................................... 67
                                      Table 53:   Cystic Fibrosis Therapeutics Market, Global, Revenue, ($m), 2002-2010 ..................... 71
                                      Table 54:   Cystic Fibrosis Therapeutics Market, Global, Revenue Forecasts, ($m), 2010-2017.... 72
                                      Table 55:   Cystic Fibrosis Therapeutics Market, Global, Geographical Segmentation, ($m), 2002-
                                                  2010 ............................................................................................................................... 73
                                      Table 56:   Cystic Fibrosis Therapeutics Market, Global, Geographical Segmentation, ($m), 2010-
                                                  2017 ............................................................................................................................... 74
                                      Table 57:   Cystic Fibrosis Therapeutics Market, Global, Annual Cost of Therapy, ($), 2002-2010 76
                                      Table 58:   Cystic Fibrosis Therapeutics Market, Global, Annual Cost of Therapy, ($), 2010-2017 76
                                      Table 59:   Cystic Fibrosis Therapeutics Market, Global, Treatment Usage Patterns, (‘000), 2002-
                                                  2010 ............................................................................................................................... 77
                                      Table 60:   Cystic Fibrosis Therapeutics Market, Global, Treatment Usage Patterns, (‘000), 2010-
                                                  2017 ............................................................................................................................... 77
                                      Table 61:   Allergic Rhinitis Therapeutics Market, Global, Revenue, ($m), 2002-2010 .................... 81
                                      Table 62:   Allergic Rhinitis Therapeutics Market, Global, Revenue Forecasts, ($m), 2010-2017 .. 82
                                      Table 63:   Allergic Rhinitis Therapeutics Market, Global, Geographical Segmentation, ($m), 2002-
                                                  2010 ............................................................................................................................... 83
                                      Table 64:   Allergic Rhinitis Therapeutics Market, Global, Geographical Segmentation, ($m), 2010-
                                                  2017 ............................................................................................................................... 84
                                      Table 65:   Allergic Rhinitis Therapeutics Market, Global, Annual Cost of Therapy, ($), 2002-2010
                                                  ....................................................................................................................................... 86
                                      Table 66:   Allergic Rhinitis Therapeutics Market, Global, Annual Cost of Therapy, ($), 2010-2017
                                                  ....................................................................................................................................... 86
                                      Table 67:   Allergic Rhinitis Therapeutics Market, Global, Treatment Usage Patterns (million), 2002-
                                                  2010 ............................................................................................................................... 87
                                      Table 68:   Allergic Rhinitis Therapeutics Market, Global, Treatment Usage Patterns (million), 2010-
                                                  2017 ............................................................................................................................... 88
                                      Table 69:   Idiopathic Pulmonary Fibrosis Therapeutics Market, Global, Revenue, ($m) 2002-2010
                                                  ....................................................................................................................................... 90
                                      Table 70:   Idiopathic Pulmonary Fibrosis Therapeutics Market, Global, Revenue Forecasts, ($m)
                                                  2010-2017 ...................................................................................................................... 90
                                      Table 71:   Idiopathic Pulmonary Fibrosis Therapeutics Market, Global, Geographical Segmentation,
                                                  ($m) 2002-2010.............................................................................................................. 91
                                      Table 72:   Idiopathic Pulmonary Fibrosis Therapeutics Market, Global, Geographical Segmentation,
                                                  ($m) 2010-2017.............................................................................................................. 92
                                      Table 73:   Idiopathic Pulmonary Fibrosis Therapeutics Market, Global, Annual Cost of Therapy, ($),
                                                  2002-2010 ...................................................................................................................... 94
                                      Table 74:   Idiopathic Pulmonary Fibrosis Therapeutics Market, Global, Annual Cost of Therapy, ($)
                                                  2010-2017 ...................................................................................................................... 94

Respiratory Disorders Therapeutics Market to 2017 - Novel                                                                                GBIHC132MR /Published SEP 2011
Pipeline Molecules such as VX-770 and pirfenidone May
Offset Negative Effect of Patent Expiries                                                                                                                                        Page 7
                                                                                       © GBI Research. This is a licensed product and is not to be photocopied
                                      Table 75: Idiopathic Pulmonary Fibrosis Therapeutics Market, Global, Treatment Usage Patterns,
                                                 (‘000), 2002-2010 ........................................................................................................... 95
                                      Table 76: Idiopathic Pulmonary Fibrosis Therapeutics Market, Global, Treatment Usage Patterns,
                                                 (‘000), 2010-2017 ........................................................................................................... 96
                                      Table 77: Bronchitis Therapeutics Market, Global, Revenue ($m), 2002-2010 .............................. 99
                                      Table 78: Bronchitis Therapeutics 
								
To top